MOTS-C
Fat LossMitochondrial-derived peptide / researchExperimental
16-aa mitochondrial-derived peptide that activates AMPK and improves insulin sensitivity in mice. Not FDA-approved.
For research use only.
Key Facts
- CAS
- 1627580-64-6
- Molecular Weight (MW)
- 2174.6 g/mol
- Half-life
- ~2-4 hours
- Unit
- mg
- Administration Route
- Subcutaneous
- Frequency
- 2-3x weekly
- Last updated
- 8/23/2026
- Targets
- AMPK pathway
Overview
16-aa mitochondrial-derived peptide that activates AMPK and improves insulin sensitivity in mice. Not FDA-approved.
Protocol
- Dosage Range
- 5-10 mg
- Frequency
- 2-3x weekly
- Cycle
- 4-12 weeks on, 4 off
- Administration Route
- Subcutaneous
- Reconstitution Guide
- 2 mL BAC for 10 mg vial
Science
Mechanism of Action
MDP that can enter cells and activate AMPK, increasing glucose utilization and fatty-acid oxidation in metabolic-disease models.
Targets
AMPK pathway
Studies
- MOTS-c metabolic MDP— Journal/year not available
Benefits
Exercise-mimetic researchInsulin-sensitivity models
Potential Side Effects
- Limited human data
- Injection reactions
References
- PMID 25738455External link · Year —